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BACKGROUND & AIMS: Alagille syndrome is a genetic
disorder characterized by cholestasis, ocular abnormalities,
characteristic facial features, heart defects, and vertebral
malformations. Most cases are associated with mutations in
JAGGED1 (JAG1), which encodes a Notch ligand, although it is
not clear how these contribute to disease development. We
aimed to develop a mouse model of Alagille syndrome to
elucidate these mechanisms. METHODS: Mice with a missense
mutation (H268Q) in Jag1 (Jag1þ/Ndr mice) were outbred to a
C3H/C57bl6 background to generate a mouse model for
Alagille syndrome (Jag1Ndr/Ndr mice). Liver tissues were
collected at different timepoints during development, analyzed
by histology, and liver organoids were cultured and analyzed.We performed transcriptome analysis of Jag1Ndr/Ndr livers and
livers from patients with Alagille syndrome, cross-referenced to
the Human Protein Atlas, to identify commonly dysregulated
pathways and biliary markers. We used species-specific
transcriptome separation and ligand-receptor interaction
assays to measure Notch signaling and the ability of JAG1Ndr to
bind or activate Notch receptors. We studied signaling of JAG1
and JAG1Ndr via NOTCH 1, NOTCH2, and NOTCH3 and resulting
gene expression patterns in parental and NOTCH1-expressing
C2C12 cell lines. RESULTS: Jag1Ndr/Ndr mice had many
features of Alagille syndrome, including eye, heart, and liver
defects. Bile duct differentiation, morphogenesis, and function
were dysregulated in newborn Jag1Ndr/Ndr mice, with aberra-
tions in cholangiocyte polarity, but these defects improved in
adult mice. Jag1Ndr/Ndr liver organoids collapsed in culture,
indicating structural instability. Whole-transcriptome sequence
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Alagille syndrome is caused by mutations in JAGGED1,
but it is unclear how specific mutations impact on Notch
signaling and affect development, and how faithfully
Jag1 mutant models mimic the human condition.
NEW FINDINGS
A receptor-selective missense mutation in mouse Jag1
(H268Q) recapitulates Alagille syndrome phenotypes in
mice. RNA seq of mouse liver samples and samples
from patients, showed that apical polarity of bile ducts
is severely disrupted.
LIMITATIONS
The mouse model is based on homozygous mutation of
Jag1, while human patients are heterozygous for JAG1
mutations.
IMPACT
This new mouse model will allow development and testing
of new therapies for Alagille syndrome, as well as a new
model in which to study how Notch signaling controls
development of organs affected by Alagille syndrome.
March 2018 Missense Jag1 Provides Alagille Insights 1081analyses of liver tissues from mice and patients with Alagille
syndrome identified dysregulated genes encoding proteins
enriched at the apical side of cholangiocytes, including CFTR
and SLC5A1, as well as reduced expression of IGF1. Exposure of
Notch-expressing cells to JAG1Ndr, compared with JAG1, led to
hypomorphic Notch signaling, based on transcriptome analysis.
JAG1-expressing cells, but not JAG1Ndr-expressing cells, bound
soluble Notch1 extracellular domain, quantified by flow
cytometry. However, JAG1 and JAG1Ndr cells each bound
NOTCH2, and signaling from NOTCH2 signaling was reduced
but not completely inhibited, in response to JAG1Ndr compared
with JAG1. CONCLUSIONS: In mice, expression of a missense
mutant of Jag1 (Jag1Ndr) disrupts bile duct development and
recapitulates Alagille syndrome phenotypes in heart, eye, and
craniofacial dysmorphology. JAG1Ndr does not bind NOTCH1,
but binds NOTCH2, and elicits hypomorphic signaling. This
mouse model can be used to study other features of Alagille
syndrome and organ development.BA
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otch signaling is a highly conserved cell-contact–*Authors share co-first authorship.
Abbreviations used in this paper: ALGS, Alagille syndrome; ECD,
extracellular domain; EGF, epidermal growth factor; FACS, fluorescence-
activated cell sorting; GSEA, gene set enrichment analyses; HPA, Human
Protein Atlas; PCA, principal component analysis; qPCR, quantitative
real-time polymerase chain reaction.
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https://doi.org/10.1053/j.gastro.2017.11.002Ndependent signaling pathway used reiteratively in
many developmental processes. Mutations in the Notch
pathway lead to numerous diseases,1 including Alagille
syndrome (ALGS1; Online Mendelian Inheritance in
Man/OMIM no. 118450, and ALGS2, OMIM no. 610205).2
ALGS is an autosomal dominant genetic disorder that
in more than 90% of patients is caused by mutations in
JAGGED1 (JAG1),3,4 while about 1% harbor NOTCH2 muta-
tions.5 Alagille syndrome often presents early in life with
severe liver and heart defects,6 but also affects vertebrae,
eyes, and craniofacial morphology.How Alagille JAG1 mutations affect signaling through
different Notch receptors is poorly understood. The JAG1
ligand is expressed on a signal-sending cell that activates
signaling upon contact with a Notch receptor on a juxta-
posed signal-receiving cell. Missense mutations in ALGS
are enriched in the receptor-binding DSL and DOS domains1
of JAG1, and analysis of the crystallized JAG1 receptor-
binding domain and an extracellular portion of NOTCH17
shows that the previously described Jag1Ndr mutation8
maps to this interaction domain, but how the JAG1Ndr muta-
tion mechanistically affects Notch signaling through receptors
other than NOTCH1 remains to be established.
Deletions in a single JAG1 allele are sufficient to cause
ALGS, suggesting haploinsufficiency is the disease-causing
mechanism. This is also supported by various mouse
models, based on targeting Jag1 and/or Notch2 (for review,
see 1). Mouse models for ALGS liver disease include condi-
tional Jag1 ablation in portal vein mesenchyme,9 and
Jag1/Notch2 compound heterozygous mice.10,11 However,
the first model does not mimic the full syndrome, and the
Jag1/Notch2 model biases our understanding of ALGS
towards Jag1/Notch2-regulated conditions, though NOTCH2
mutations are observed in only a fraction of ALGS cases.12
Also, NOTCH2-related ALGS2 presents differently from
JAG1-related ALGS1; for example, patients with NOTCH2
mutations less frequently display heart defects.13 Jag1þ/dDSL
mice on a C57bl6 background display bile duct paucity but
are not jaundiced,14 and it is unknown whether these mice
recapitulate other major features of ALGS. Thus, the link
between missense Jag1 mutations and ALGS has not yet
been possible to address in vivo.
In this report, we show that a missense mutation in Jag1
(H268Q; Nodder, Jag1Ndr 8) generates a mouse model for
ALGS, mimicking disease pathology in eye, craniofacial
morphology, heart, and liver. By investigating liver develop-
ment at different stages, and using liver organoids from
Jag1Ndr/Ndr mice, we show that while biliary differentiation is
delayed, biliary morphogenesis and maintenance are dis-
rupted. In line with dysregulated morphogenesis, whole
transcriptome analysis of ALGS liver biopsies and Jag1Ndr/Ndr
livers confirms dysregulated expression of cell polarity genes,
but not of key regulators of bile duct differentiation at post-
natal or adult stages. At the molecular level, the JAG1Ndr
mutation generates a hypomorphic ligand that is unable to
bind to specific Notch receptors: JAG1Ndr binds NOTCH2, but
not NOTCH1, and to a lesser degree NOTCH3. Collectively, we
show that a missense mutation in Jag1 is sufficient to invoke
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that a Jag1 missense mutation can impact differentially on
different Notch receptor interactions.
Methods
Mouse Maintenance, Breeding, and Genetics
Jag1þ/Ndr mice have been described previously,8 and for the
present study were maintained in a mixed C3H/C57bl6 genetic
background. For details, see Supplementary Materials.
Measurement of Craniofacial Proportions
The distance from the eye to the snout tip and from the
snout/forehead bridge to the snout tip were measured using
ImageJ in images of E15.5 embryos taken from the animal’s
right side. All measurements were performed by experimenters
blinded to the genotype.
Antibodies, Immunohistochemistry, and Staining
Fourteen-mm cryosections of liver were stained using
routine staining protocols. For antibodies and staining details,
see Supplementary Materials.
Bile Duct Quantification
Bile ducts in 10–100 portal triads were quantified per stage
in Jag1þ/þ and Jag1Ndr/Ndr mice. For details, see Supplementary
Materials.
Blood Chemistry Analysis
Plasma and serum were sent to the Swedish University of
Agricultural Sciences for analysis of blood chemistry. For
details, see Supplementary Materials.
Quantitative real-time polymerase chain
reaction (qPCR)
qPCR was performed, as described.15 For primers see
Supplementary Materials.
Liver Organoid Cell Culture
Liver organoids were isolated and cultured, as described,16
in the presence of R-spondin.
Collection of Human Samples for RNA
Sequencing
Human liver needle biopsies were collected for clinical
purposes, and a small part (3–5 mm x 1 mm) was snap-frozen
and stored at -80C. Diagnosis details are in Supplementary
Materials.
Tissue Dissection, Homogenization, RNA
Extraction, and cDNA Library Preparation
Liver was homogenized and RNA from liver or cells was
extracted using Direct-zol RNA MiniPrep (cat. no. R2050; Zymo
Research, Irvine, CA) or the RNeasy Mini Kit (cat. no. 74104;
Qiagen, Hilden, Germany).
cDNA libraries for all samples were created using the
TruSeq RNA Sample Prep Kit v2–48, Set A (cat. no. RS-122-2001;Illumina, San Diego, CA) and Set B (cat. no. RS-122-2002;
Illumina). For specifics, see Supplementary Materials.
Alignment, Analysis of Technical Performance,
and Bioinformatics
The cDNA libraries were sequenced on a HiSeq 2000 with
a 50–52 read length, single-end, for different samples.17
Bioinformatics and sequencing details are provided in
Supplementary Materials.
Human Protein Atlas Cross-referencing
Enrichment of Bile Duct Genes
Proteins expressed in bile ducts were identified using the
Human Protein Atlas (HPA, http://www.proteinatlas.org/),18
using the following search string: Field: Tissue expression
(IHC), Tissue: Liver, Cell Type: Bile duct cells, Expression: High
or Medium AND Field: Tissue expression (IHC), Tissue: Liver,
Cell Type: Bile duct cells, Expression: Not detected or low.
Supplementary Tables 5–8. For details, see Supplementary
Materials.
Bile Duct Orientation by ZO-1 Staining
in Adult Mice
ZO-1 orientation analysis was carried out in 6–12 well-
formed/functional bile ducts per animal (n¼3).
IGF1 ELISA
IGF1 in serum was detected using ELISA according to
manufacturer’s instructions (cat. no. EMIGF1; Thermo Fisher
Scientific, Waltham, MA).
Cell Lines and Cell Culture
Mouse C2C12 control and C2C12-FLNotch1 and human
HEK-293-Flp-In cells8: HEK293-Flp control (Flp Ctrl), HEK293-
Flp-Jag1WT (Flp JAG1þ), HEK293-Flp-Jag1Ndr (Flp JAG1Ndr)
were used. For culture conditions and luciferase experiments,
see Supplementary Materials.
Notch ECD Uptake Experiments
NOTCH1-Fc, NOTCH2-Fc, and NOTCH3-Fc (R&D Systems,
Minneapolis, MN) was coupled to Alexa 488 anti-Fc (Invitrogen,
Carlsbad, CA). Flp Ctrl, Flp JAG1þ, and Flp JAG1Ndr cells were
treated with the tagged proteins for 1 hour at 37C. Cells
were stained for confocal imaging or trypsinized for fluorescence-
activated cell sorter fluorescence-activated cell sorting (FACS)
analysis, as described in Supplementary Materials.
Statistical Analysis
Differences between control and experimental conditions
were tested using t test, 1-way ANOVA, or 2-way ANOVA. For
specifics, see Supplementary Materials.
Results
Jag1Ndr/Ndr Mice Recapitulate Alagille Syndrome
We previously described a mouse Jag1 mutation
(H268Q) in the second epidermal growth factor (EGF)-like
Figure 1. Jag1Ndr/Ndr C3H/C57bl6 mice survive to adulthood with Alagille-like phenotypes. (A) Jag1þ/Ndr mice were mated to
generate Jag1þ/þ, Jag1þ/Ndr and Jag1Ndr/Ndr offspring. At P10 and adult stages, fewer than the expected 25% of Jag1Ndr/Ndr
mice were observed. (B, C) At E15.5 Jag1Ndr/Ndr mice appear grossly normal, with a mild eye defect (B), and by P10 are smaller
and jaundiced (C). (D) After birth, 20% of Jag1Ndr/Ndrmice die within the first 20 days. (E) At birth, Jag1Ndr/Ndr mice are of normal
size, but fail to gain weight as rapidly, a difference that is significant from P2, and (F) persistently weigh less than wild types. (G)
Jag1Ndr/Ndr hearts are somewhat smaller than wild type hearts, likely corresponding to the smaller size of Jag1Ndr/Ndr mice.
Hematoxylin staining of cryosections reveals ventricular (asterisk) and atrial (boxed) septation defects. (H) Iris dysmorphologies
are manifested in Jag1Ndr/Ndr mice as early as E15.5. (I) Craniofacial proportions were measured in photos of E15.5 embryos,
measuring the distance from (J) the eye to the tip of the snout and (K) the snout bridge to the tip of the snout, revealing a
tendency towards altered proportions. For J and K, 3 animals were measured for Jag1þ/Ndr and Jag1Ndr/Ndr, but only 1 Jag1þ/þ.
Error bars indicate s.d.; **P <.01, ****P <.0001.
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in ALGS.1 This allele is nicknamed Nodder (Jag1Ndr) because
of a head-nodding phenotype in heterozygous C3H mice.Jag1Ndr/Ndr mice are embryonic lethal on this genetic
background8 and, because the phenotype of other Jag1
heterozygous mice depends on genetic background,14,19 we
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and recapitulate ALGS.
On a mixed C3H/C57bl6 background, viability was
considerably improved: Jag1Ndr/Ndr embryos were recov-
ered at a rate of 20% at embryonic day (E) 15.5, 10% from
postnatal day (P) 0, and 5% in adults (Figure 1A,
Supplementary Table 1, and data not shown). At E15.5,
Jag1Ndr/Ndr embryos appeared grossly normal, and only
exhibited a mild iris dysmorphology (Figure 1B). In contrast,
postnatal Jag1Ndr/Ndr pups were jaundiced (Figure 1C),
excreted yellow stools (data not shown), exhibited partial
post-natal mortality (Figure 1D), and failed to thrive
(Figure 1E). Adult Jag1Ndr/Ndr mice were 30% smaller than
Jag1þ/þ and Jag1þ/Ndr mice (Figure 1F).
ALGS is diagnosed based on the presence of
cholestasis, ocular abnormalities, characteristic facial
features, heart defects, and vertebral malformations.6 The
heart defects range from pulmonary artery stenosis to
tetralogy of Fallot, a severe defect encompassing pulmo-
nary stenosis, overriding aorta, ventricular septal defect,
and right ventricular hypertrophy.20 Both atrial and ven-
tricular septation defects were present in E15.5 and P0
Jag1Ndr/Ndr mice (Figure 1G and Supplementary
Figure 1A).
Patients with ALGS display posterior embryotoxon,12 a
malformation attributed to neural crest defects,21 and a
smaller cornea.22 The first obvious phenotype in Jag1Ndr/Ndr
mice was bilateral iris deformation with dorsal constriction
at E13.5, which progressed to severe deformities and
occasionally micropthalmia by P10 (Figure 1B,H, and
Supplementary Figure 1B). Jag1Ndr/Ndr lenses were similar
to wild types in size at E15.5 and were only slightly smaller
at P10 (Supplementary Figure 1C,D), while 30% of adult
Jag1Ndr/Ndr mice exhibited micropthalmia (data not shown).
Craniofacial alterations, including a broad prominent
forehead, deep-set eyes, and a pointy chin, are seen in 77%–
96% of patients.12 Jag1Ndr/Ndr mice similarly displayed a
tendency toward altered craniofacial proportions with a
wild type eye-nose length (Figure 1I,J), but a reduced snout
length (bridge to tip, Figure 1I,K), supporting a role for Jag1
in craniofacial development, in line with previous reports.23
Alcian blue/Alizarin red staining of cartilage and bone at P0
and P10 did not reveal obvious vertebral malformations
(data not shown), indicating that butterfly vertebrae12 are
probably not present in Jag1Ndr/Ndr mice.
In conclusion, Jag1Ndr/Ndr mice recapitulate cardinal
features of ALGS, including ocular, craniofacial, and cardiac
defects. Jaundice indicates liver dysfunction, and we=
Figure 2. Postnatal Jag1Ndr/Ndr mice display ductopenia, which
show a marked absence of biliary cells at E18.5 (A) and weak
KRT19þ cell clusters appear around ASMAþ periportal regions n
in Jag1Ndr/Ndr mice. (E, F) By P10, clusters of biliary cells have lu
mice. Jag1Ndr/Ndr mice display increased (G) alkaline phospha
bilirubin (Bil Dir), and (J) decreased albumin. (K) At adult sta
Jag1Ndr/Ndr mice, though classification (L) of structures shows
well-formed bile ducts. (N) Nevertheless, markers of liver fun
Jag1Ndr/Ndr mice in most serum chemistry markers. A small diffe
indicate s.d.; *P <.05, **P <.01, ***P <.001, ****P <.0001. Scaletherefore next asked whether Jag1Ndr/Ndr mice display
ductopenia.Jag1Ndr/Ndr Mice Exhibit Early Life Biliary
Dysmorphogenesis and Dysfunction
With Later Rescue
A crippling ALGS symptom is cholestatic liver disease,
with conjugated hyperbilirubinemia and decreased liver
function, which histologically is associated with paucity of
intrahepatic bile ducts. Thus, liver transplantation is frequently
required. The pathomechanisms for ductopenia are poorly
understood and it is unclear why, in some patients, cholestasis
diminishes with time.24,25 Because some Jag1Ndr/Ndr mice sur-
vive to adulthood, the model provides an opportunity to
elucidate disease development across different stages.
Jag1Ndr/Ndr mice displayed strong jaundice at neonatal
stages (Figure 1C), whereas surviving adult Jag1Ndr/Ndr mice
did not display jaundice, nor excrete yellow feces (data not
shown). To determine whether Jag1Ndr/Ndr mice manifest a
transient biliary phenotype, we analyzed biliary histology
and marker expression in portal regions during develop-
ment. Both Sox9 (a Notch target gene that regulates bile
duct development26) and Hnf1b were present in Jag1þ/þ
periportal areas, but absent in Jag1Ndr/Ndr mice at E18.5. At
p0, faintly positive cells were detected around portal tracts
in Jag1Ndr/Ndr mice, at levels far weaker than the clusters of
Sox9/Hnf1b-positive cells undergoing lumen formation in
Jag1þ/þ livers. At this stage, Jag1Ndr/Ndr hilar portal regions
had no morphologically discernible mature bile ducts, while
3.3% of Jag1þ/þ hilar portal veins had adjoining mature bile
ducts (Figure 2C,D). The majority of P0 portal veins in
Jag1Ndr/Ndr livers contained either no KRT19þ cells or
disorganized clusters of KRT19þ cells (Figure 2B–D,
Supplementary Figure 2A). At P10, bile ducts were rarely
found in Jag1Ndr/Ndr livers, while portal veins in Jag1þ/þ
livers manifested 1 or 2 adjacent mature bile ducts
(Figure 2E,F; Supplementary Figure 2B,C). Hepatoblast and
hepatocyte marker expression levels were unaltered (data
not shown), but serum biochemistry at P10 confirmed that
Jag1Ndr/Ndr liver function was severely compromised
(Figure 2G–J, Supplementary Figure 2D–F).
In contrast, lumenized bile ducts could be found in both
Jag1þ/þ and Jag1Ndr/Ndr adult mice, though with disrupted
morphology in Jag1Ndr/Ndr livers (Figure2K–M, Supplementary
Figure 2G,H). We classified and quantified pan-cytokeratinþ
and KRT19þ bile ducts as “well-formed” (1 layer of biliary
cells, a round lumen), “functional” (1 or more layers of biliaryis rescued in adults. (A, B) HNF1b, SOX9, and KRT19 staining
staining at P0 (B) near the hilum in Jag1Ndr/Ndr liver. (C, D)
ear the hilum of wild type Jag1þ/þ mice at P0, but are absent
menized to form ducts in Jag1þ/þ mice, but not in Jag1Ndr/Ndr
tase (ALP), (H) aspartate aminotransferase (ASAT), (I) direct
ges, lumenized bile ducts are present in both Jag1þ/þ and
(M) significantly more clusters in Jag1Ndr/Ndr mice and fewer
ction demonstrate a rescue of bile duct function in adult
rence in aspartate aminotransferase levels persists. Error bars
bars: (A, B) 50 mm, (C) 20 mm, (I, J) 10 mm.
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no discernible lumen) (Figure 2L). Adult Jag1Ndr/Ndr mice
harbor fewer “well-formed” bile ducts and instead contain
“clusters” of biliary cells (Figure 2M, Supplementary
Figure 2G). However, there was no significant difference
between Jag1þ/þ and Jag1Ndr/Ndr mice when grouping well-
formed and functional bile ducts (Supplementary Figure 2H).
Serum analysis confirmed a full functional recovery in adult
Jag1Ndr/Ndr mice (Figure 2N, Supplementary Figure 2I,J), with
only a small difference in aspartate aminotransferase levels
still detectable.
In contrast to the transient biliary phenotype, there was
a persistent absence of hepatic arteries in Jag1Ndr/Ndr mice
(Figure 2K, Supplementary Figure 2K,L). In conclusion, the
Jag1Ndr/Ndr mice display a biliary phenotype that is severe at
early postnatal stages but that improves during adulthood.
Disrupted Bile Duct Morphogenesis
and Delayed Differentiation
It is unclear whether the ALGS biliary defects are
because of disrupted morphogenesis,11 differentiation de-
fects,27 or both.28 To address this question, we analyzed the
expression of key genes regulating differentiation. Expres-
sion of Sox9, and Hnf4a, a transcription factor required for
hepatocyte differentiation,29 as well as alfa-fetoprotein (a
marker of hepatoblasts) and albumin (a marker for hepa-
tocyte function), was unaffected in P10 and adult Jag1Ndr/Ndr
mice (Figure 3A–F, data not shown). Similarly, SOX9 mRNA
levels were not affected in ALGS liver biopsies (Figure 3G),
nor were the well-characterized biliary markers HNF1b or
KRT19 (Figure 3H,I). This is in contrast to the early absence
of SOX9- and HNF1b-positive cells at E18.5 and P0
(Figure 2A,B).
To assess adult bile duct development and morphology,
we used a recently developed model for long-term in vitro
expansion of bile duct-derived progenitor cells.16,30 Bile
duct fragments were hand-picked and cultured in vitro as
liver organoids, forming readily from both adult control and
Jag1Ndr/Ndr mice. Notch2, Hes1, Hnf4a, Sox9, and Hnf1b
mRNA expression were not altered (Figure 3J–N), further
supporting that differentiation was delayed, but not
completely inhibited (see Figure 2). However, liver orga-
noids from Jag1Ndr/Ndr mice grew less well than Jag1þ/þ
organoids (Figure 3O). Importantly, a number of Jag1Ndr/Ndr
organoids collapsed in culture after 5–6 days (Figure 3P),
demonstrating structural instability. Jag1Ndr/Ndr biliary cells
from adult mice are therefore similar to Jag1þ/þ biliary cells
in terms of cell identity, but exhibit differences in structural
stability. In conclusion, the data argue for morphologic as
well as differentiation defects.=
Figure 3. Jag1Ndr/Ndr biliary cells express the expected markers
P10 at the mRNA level (A), and at adult stages at protein levels (B
show no significant differences in Jag1Ndr/Ndr mice at P10. Simila
SOX9, (H) HNF1b, or (I) KRT19 levels. Organoids derived from ad
Hes1, (L) Hnf4a, (M) Sox9, and (N) Hnf1b as assessed by qP
collapsed. Collapse was not related to organoid size because
were significant. Scale bar: (B) 10 mm.Novel Biomarkers for Alagille Syndrome Reveal
Dysregulation of Apical Proteins
To further assess the molecular basis for ALGS,
we performed genome-wide transcriptome studies of
liver biopsies from 5 patients with ALGS. Control samples
from pediatric patients with liver disease and/or chol-
angiopathies allow us to detect genes specifically dysregu-
lated in ALGS, rather than cholestasis pathways or general
liver disease mechanisms. Principal component analysis
(PCA) showed that the 5 ALGS liver transcriptomes clus-
tered with the 2 cholangiopathy samples: autoimmune
hepatitis with primary sclerosing cholangitis, and progres-
sive familial intrahepatic cholestasis type 2. In contrast, the
transcriptomes from 2 patients with autoimmune hepatitis
segregated more distinctly (Figure 4A, Supplementary
Table 2). There were 191 up-regulated and 139 down-
regulated genes (adjusted P value <.1, fold change >1.5,
Figure 4B, Supplementary Tables 3 and 4, Supplementary
Figure 3).
The transcriptome data are derived from bulk liver. We
therefore devised a strategy to cross-reference the tran-
scriptome data with protein expression patterns from the
HPA (http://www.proteinatlas.org), a map of the human
proteome,18 allowing us to identify genes encoding proteins
expressed in bile ducts (Figure 4C, Supplementary
Tables 5–8). This strategy identified the well-established
biliary markers HNF1b, KRT19, and SOX9, confirming
strategy validity and specificity, and HPA data showed the
expected biliary expression (Supplementary Figure 4A).
Comparison of HPA bile duct-enriched proteins to ALGS
transcriptomes revealed 5 up-regulated and 7 down-
regulated novel bile duct markers in ALGS (Figure 4D,E,
Supplementary Figure 4B–L). Of these, FXYD domain con-
taining ion transport regulator 3 (FXYD3, Figure 4D) and
Solute carrier family 5 (sodium/glucose cotransporter)
member 1 (SLC5A1, Figure 4E) showed the highest signifi-
cance, and encode proteins enriched at the apical surface of
bile ducts. Manual comparison of the protein localization of
the top 30 down-regulated genes to the HPA revealed 5
additional bile duct-specific genes with apical cholangiocyte
staining including Cystic Fibrosis Transmembrane Conduc-
tance Regulator (CFTR, Figure 4F), Carbohydrate Sulfo-
transferase 4 (CHST4, Figure 4G), Claudin 10 (CLDN10,
Figure 4H), Interleukin 1 receptor-like 1 (IL1RL1, Figure 4I)
and Solute Carrier Family 6 (Neutral Amino Acid Trans-
porter) member 19 (SLC6A19, Figure 4J). Given this link to
aberrant cell polarity, we assessed the distribution of Zona
occludens 1 (ZO-1, a.k.a. TJP-1), a marker of apical junctions
in cholangiocytes that is not down-regulated in ALGS or in
Jag1Ndr/Ndr mice (data not shown). Even in the best-formedbut display structural instability. Sox9 levels are unchanged at
, C). qPCR for (D) alpha-fetoprotein, (E) albumin, and (F) Hnf4a
rly, RNA sequencing of ALGS livers shows no difference in (G)
ult Jag1Ndr/Ndr livers expressed normal levels of (J) Notch2, (K)
CR, but (O) grew slowly and (P) sometimes spontaneously
both smaller and larger organoids collapsed. No differences
Figure 4. RNA sequencing of ALGS liver reveals a specific decrease in apical markers of biliary cells. (A) Principle component
analysis (PCA) of RNA sequencing of liver biopsies from patients with ALGS or control patients. A comparison with non-
cholestatic control samples (Ctrl 1 and 2) and with cholestatic control samples (Ctrl 3 and 4) shows that ALGS samples cluster
with cholestatic liver samples. (B) Heatmap shows 191 significantly up-regulated and 139 down-regulated genes in ALGS
samples. (C) Dysregulated genes were compared with protein lists generated using the HPA (www.proteinatlas.org)18 for
genes with high/medium protein expression in biliary cells, and undetected/low expression in hepatocytes (Supplementary
Tables 5–8). This pipeline identified transcripts whose proteins were highly enriched at the apical side of bile ducts,
including (D) FXYD3, and (E) SLC5A1. Manual comparison of the top 30 down-regulated genes in ALGS further revealed
apically enriched proteins: (F) CFTR, (G) CHST4, (H) CLDN10, (I) IL1RL1, and (J) SLC6A19. (K) TJP1/ZO-1 is not down-
regulated but is aberrantly localized, with some junctions (L) missing ZO-1, and other cell junctions with (M) extra ZO1
punctae. Error bars indicate s.d.; **corrected P-value (False Discovery Rate) <.01, ***False Discovery Rate <.001, ****False
Discovery Rate <10
ˇ
-7. Scale bar: 5 mm.
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firming polarity defects (Figure 4K–M). In conclusion, the
most highly down-regulated biliary genes encode proteins
enriched at the apical surface of bile ducts, corroborating
morphogenesis disruption in ALGS.ND L
BI
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AR
YIgf1 is Down-regulated in Patients With ALGS
and Jag1Ndr/Ndr Mice
We next compared the transcriptomic changes in
Jag1Ndr/Ndr livers to ALGS livers. RNA sequencing of
Jag1Ndr/Ndr and Jag1þ/þ livers yielded distinct transcrip-
tional profiles (Figure 5A, Supplementary Table 9), with 679
up-regulated and 374 down-regulated genes (Figure 5B,
Supplementary Tables 10 and 11, and Supplementary
Figure 5).
We assessed changes in signaling pathways and major
cellular programs using gene set enrichment analyses
(GSEA), which identified 35 sets significantly enriched in
Jag1Ndr/Ndr livers at False Discovery Rate <25% (Figure 5C,
Supplementary Tables 12 and 13, GSEA in Supplementary
Figure 6). In contrast, GSEA for the ALGS transcriptome
showed 6 enriched gene sets (Supplementary Tables 14
and 15, Supplementary Figure 7).
We next examined genes that were up- or down-
regulated in both ALGS livers and in Jag1Ndr/Ndr livers.
Sixteen genes were up-regulated (Figure 5D) and 2 were
down-regulated (Figure 5E) in both transcriptomes. This
relatively small degree of overlap is likely explained by
the use of different controls in the 2 experiments (non-
ALGS liver pathologies for patient data, and Jag1þ/þ for
mouse data), and innate differences between humans and
mice, as well as in age. To test whether the use of
different controls revealed different aspects of disease,
we compared ALGS liver transcriptomes with the chol-
angiopathic and non-cholangiopathic controls separately
(Supplementary Figure 8A–C). A greater numbers of
enriched gene sets and dysregulated genes were detected
when ALGS livers were compared with non-cholangiopathic
livers (Supplementary Figure 8D–G, Supplementary
Tables 16–19), than when ALGS livers were compared
with cholangiopathic livers (Supplementary Figure 8H–K,
Supplementary Tables 20–23), indicating general chol-
angiopathic transcriptomic responses are additionally
revealed when non-cholestatic patients are included as
controls. This is corroborated by the higher general overlap
of this dataset with the Jag1Ndr/Ndr results (Supplementary
Figure 8D–K). In all analyses, Igf1 (Insulin like growth fac-
tor 1) emerges as a target of particular interest.
Down-regulation of Igf1 in ALGS and in Jag1Ndr/Ndr mice
is in line with a previous report showing that IGF1 is not=
Figure 5. IGF1 is dysregulated in Jag1Ndr/Ndr and Alagille liver.
(A) PCAofRNAsequencing reveals thatJag1þ/þandJag1Ndr/Ndr
liver transcriptomes cluster distinctly. (B) Heatmap shows 679
significantly up-regulated and 374 down-regulated genes in
Jag1Ndr/Ndr livers. (C) Comparison of Gene Set Enrichment
Analyses (GSEA), of livers from Jag1Ndr/Ndr mice and patients
with ALGS (Supplementary Tables 12–15) shows extensive
overlap. (D) Comparison of significantly dysregulated genes
shows (D) 16 genes up-regulated and (E) 2 genes down-
regulated in both Jag1Ndr/Ndr mice and ALGS, including Igf1.
Igf1 mRNA levels are highly down-regulated in Alagille livers
(F) and Jag1Ndr/Ndr livers (G). IGF1 protein levels were confirmed
tobedown-regulated in serumof (H) P10and (I) adultmice. Error
bars indicates.d.; **P<.01, ***P<.001. (InF, andG,P-valuesare
corrected P-values).
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RYup-regulated upon administration of growth hormone to
patients with ALGS and growth deficiencies.31 The reduced
expression of Igf1 in patients (Figure 5F) and in Jag1Ndr/Ndr
mice (Figure 5G), which we confirmed with ELISA of
serum from P10 and adult Jag1Ndr/Ndr mice (Figure 5H,I), is
also likely to explain the Jag1Ndr/Ndr growth defects
(Figure 1C,E,F).
JAG1Ndr Elicits Hypomorphic Notch Signaling
To address how the JAG1Ndr mutation influences
signaling downstream of Notch, we analyzed the genome-
wide transcriptomic response in NOTCH-expressing cells
following activation by JAG1þ or JAG1Ndr. To specifically
monitor the Notch response, we co-cultured mouse receptor
cells (C2C12) with human ligand cells (HEK293 Flp)
(Figure 6A). The transcriptome of C2C12 cells was bio-
informatically separated from the HEK293 transcriptome
based on species-specific sequencing (S3, Figure 6B,
Supplementary Figure 9), which separates more than 99%
of a mixed transcriptome to the correct species.17 Notch
target gene responses were specifically detectable in the
Notch receptor-expressing (mouse) cell reads in conditions
with Notch activation (Figure 6C–F, Supplementary
Figure 10A–D).
We co-cultured ligand-expressing HEK293 Flp cells with
control C2C12 cells (which express Notch2 and Notch3 at
twice the levels of Notch1 and with almost undetectable
Notch4 [Supplementary Figure 10E]), or with NOTCH1-
overexpressing C2C12 cells, to examine whether NOTCH1
modified the transcriptomic response induced by ligand-
expressing cells. PCA of the mouse transcriptomes showed
that the JAG1Ndr-induced transcriptome is intermediate
between response to control cells, and response to JAG1þ-
expressing cells (Figure 6G, Supplementary Table 24).
However, in C2C12 cells, which predominantly express
Notch2 and Notch3, the JAG1Ndr-induced transcriptome
clustered with the JAG1þ-induced transcriptome, whereas
for NOTCH1-overexpressing C2C12 cells, the JAG1Ndr tran-
scriptome lay closer to the Ctrl-induced transcriptome.
This suggests that JAG1Ndr signals weakly or not at all
through NOTCH1, in line with our previous report.8 In
addition, Notch target genes showed weak (10%–80%)=
Figure 6. JAG1Ndr is a Notch signaling hypomorph with recept
nations. Control or NOTCH1-overexpressing C2C12 cells (mous
JAG1Ndr cells (human cells, red). (B) After 6 hours, RNA was extr
analyses separates mouse from human reads. The Notch targ
receptor cells upon simulation with Flp JAG1þ cells, (E, F) but no
shows that control and NOTCH1-overexpressing C2C12 cell li
wards shift, reflecting Notch activation. JAG1Ndr is only capabl
C2C12 cells, but behaves similar to JAG1þ in its activation o
does bind NOTCH2 and NOTCH3. Flp Ctrl, Flp JAG1þ, or Flp JA
domain of NOTCH1, 2, or 3 (N1-3ECD, white). After 1 hour of u
endocytosed, cell surface N1-3ECD (green), or cells were sub
3ECD. Flp JAG1þ cells bind and internalize NOTCH1, 2, an
NOTCH2 and NOTCH3. FACS analysis of N1ECD uptake by (I) F
in (L). FACS analysis of N2ECD uptake by (M) Flp Ctrl cells, (N
analysis of N3ECD uptake by (Q) Flp Ctrl cells, (R) Flp JAG1þ, or
show Overton cumulative histogram subtractions. Error bars ind
from 1 experiment. Scale bar: (H) 10 mm.up-regulation by the JAG1Ndr ligand (Supplementary
Figure 10F). In sum, the JAG1Ndr allele is hypomorphic at
the global transcriptome level with regard to its ability to
elicit Notch signaling.JAG1Ndr Induces Receptor-selective Binding
The differentially hypomorphic signaling elicited by
JAG1Ndr suggested that JAG1Ndr-mediated signaling through
Notch receptor paralogs may be altered. Because the
H268Q mutation resides in the Notch receptor-interacting
domain, we tested whether JAG1Ndr exhibited receptor
paralog-specific binding. Flp JAG1þ or Flp JAG1Ndr ligand-
expressing cells were treated with fluorescently tagged
soluble NOTCH1-3 receptor extracellular domain peptides
(N1-3ECD, Figure 6H). Immunocytochemistry for the
NECD-Fc was performed, without permeabilization, to
detect extracellular ECDs (Figure 6H). N2ECD and N3ECD
were bound by Flp JAG1þ and Flp JAG1Ndr cells, whereas
N1ECD only interacted with Flp Jag1þ (Figure 6H); the
latter in keeping with our previous report.8 FACS analysis
showed that N1ECD was internalized by 50% of Flp JAG1þ
cells, while Flp JAG1Ndr cells did not significantly inter-
nalize N1ECD (Figure 6I–L, Supplementary Figure 10G). In
contrast, N2ECD was internalized by 80% of Flp JAG1þ
cells, and by 70% of Flp JAG1Ndr cells (Figure 6M–P).
However, the amount of N2ECD internalized by Flp JAG1Ndr
cells was lower than by Flp JAG1þ cells (Supplementary
Figure 10H). N3ECD was internalized by 35% of Flp
Jag1þ cells, and by 20% of Flp Jag1Ndr cells (Figure 6Q–T,
Supplementary Figure 10I). Because N2ECD internalization
was reduced, we next tested the extent of activation of cells
expressing Notch2 receptors, in response to co-culture
with cells expressing Flp JAG1þ or Flp JAG1Ndr. Co-
culture with Flp JAG1Ndr cells resulted in reduced Notch
activation (as defined by 12XCSL-luciferase activation), as
compared with co-culture with Flp JAG1þ cells
(Supplementary Figure 10J). In conclusion, Flp JAG1Ndr
exhibits a selective loss of interaction with NOTCH1, but
the interaction with NOTCH2 and NOTCH3 is partially
retained, although NOTCH2-mediated signaling elicited by
Flp JAG1Ndr is reduced.or-selective binding. (A) Scheme depicting co-culture combi-
e cells, blue) were co-cultured with Flp Ctrl, Flp JAG1þ, or Flp
acted for species-specific RNA sequencing (S3). Bioinformatic
et genes, Nrarp and Heyl, are (C, D) up-regulated in mouse
t in human ligand cells. (G) PCA for the mouse transcriptome
nes both respond to JAG1þ stimulation with a similar down-
e of inducing part of this response in Notch1-overexpressing
f C2C12 cells. (H–T) JAG1Ndr does not bind NOTCH1 but
G1Ndr cells were treated with fluorescently tagged extracellular
ptake, cells were fixed and anti-Fc was used to detect non-
jected to FACS analysis. (H) Flp Ctrl cells do not bind N1-
d 3. Flp JAG1Ndr cells do not bind NOTCH1, but do bind
lp Ctrl cells, (J) Flp JAG1þ, or (K) Flp JAG1Ndr cells, quantified
) Flp JAG1þ, or (O) Flp JAG1Ndr cells, quantified in (P). FACS
(S) Flp JAG1Ndr cells, quantified in (T). Quantifications (L, P, T)
icate s.d.; *P <.05, **P <.01, ***P <.001. C–G represent results
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ALGS is usually caused by mutations in the JAG1 gene,
but how dysregulated Notch signaling links to phenotypic
consequences has been enigmatic. In this report, we
provide evidence that a Jag1 missense mutation
(Jag1H268Q) recapitulates Alagille symptoms in a number
of organs. Jag1H268Q elicits a reduced Notch tran-
scriptomic response and Notch receptor-selective binding
(schematically depicted in Figure 7).
Disturbed Morphogenesis in Jag1Ndr Bile Ducts
The Jag1Ndr/Ndr mouse demonstrates that a Jag1
missense mutation can recapitulate ALGS. Other models
based on loss-of-function Jag1 and/or Notch2 alleles do
not display the entire spectrum of disease phenotypes.
The Jag1Ndr/Ndr mouse displays Alagille-like phenotypes in
several organs, including heart, lens, and craniofacial
structures, as well as liver, and thus represents a clinically
relevant mouse model for ALGS. An important distinction
must be made, however, with regards to genetics: ALGS in
humans is generally caused by heterozygosity for JAG1,
while in mice the phenotype arises in the homozygous
Jag1Ndr/Ndr state.
The fact that Jag1Ndr/Ndr mice survive to adulthood
provides an opportunity to explore liver pathology over a
lifetime. Interestingly, despite neonatal ductopenia, the
number of bile ducts increases in the adult – although with
aberrant morphology. In keeping with this, cholestasis was
pronounced in pups, while adults display a full recovery
regarding cholestasis, suggesting compensatory mecha-
nisms rescue ductopenia in Jag1Ndr/Ndr mice. To what
extent recuperation of the liver occurs also in ALGS is
contested because some patients recover from cholestasis
with time32 while in others biliary breakdownFigure 7. Schematic summary of phenotypes and signaling a
mutation, organs with phenotypes described here, and the i
receptors are depicted.continues.24,25 Some patients display regenerating liver
nodules with normal bile duct numbers.24,33,34 The RNA
sequencing of ALGS liver samples (Figure 4) showed some
heterogeneity, and in light of the variable liver disease
severity and progression or reversal, additional analyses
on bigger cohorts of patients will be necessary to deter-
mine whether there is a unifying molecular mechanism
leading to bile duct abnormalities and whether diseases
progression can be predicted based on transcriptomic data.
The notion of a transient liver phenotype is also of interest
for therapy; if cholestasis could be temporarily treated,
then harnessing endogenous repair mechanisms could
reduce the need for liver transplantation. In this context,
the Jag1Ndr/Ndr mouse may serve as an important tool to
explore novel therapeutic strategies, to test if transplanted
cells can give rise to bile ducts, or which treatments induce
repair mechanisms.
The Jag1Ndr/Ndr mice also shed light on the nature of the
ALGS biliary pathology, attributed to disrupted morpho-
genesis of the bile ducts,11 defective bile duct maintenance,
or differentiation defects.27,28 Our data indicate that
morphogenesis and maintenance of bile ducts are affected,
in addition to differentiation. This notion is supported by
profound changes in gene expression in ALGS affecting cell
polarity, at postnatal and adult stages. Further support for
disturbed morphogenesis comes from the liver organoid
data, in which Jag1Ndr/Ndr organoids initiated growth but
collapsed a few days later, supporting structural rather than
developmental defects. A previous report showed that liver
organoids from human Alagille livers showed no phenotype
in the undifferentiated state, but underwent collapse and
apoptosis upon R-spondin withdrawal.30
Dysregulated cell polarity by disrupted Notch signaling
has been shown in other polarized structures. Removal ofberrations in Jag1Ndr/Ndr mice. The location of the JAG1Ndr
nteraction and signaling dysregulation for individual Notch
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stem cells disrupts neural rosettes,35 a lumenized and
polarized colony of neural cells modeling the neural
tube in vitro. Similarly, in the zebrafish lateral line,
Notch is required for apical constriction of proneuromast
rosettes,36 and regulates apical junction-associated
genes, which together with our results, indicates a more
general interaction between Notch and the cell polarity
machinery.
The Jag1Ndr Mutation Causes Hypomorphic
Signaling and Receptor Selectivity
Our data lend support to the hypomorphic view of ALGS
mutations. The transcriptome data from co-cultured ligand-
and receptor-expressing cells indicate that Jag1Ndr induces a
hypomorphic Notch signaling response.
The finding that the H268Q mutation yields a JAG1
ligand that selectively loses its ability to interact with and
activate NOTCH1, while maintaining interaction with
NOTCH2 and 3, provides a novel facet of Notch signaling.
Modifications of NOTCH receptors by Fringe fine-tunes
their interaction with JAG or DLL ligands, but that a
ligand mutation is sufficient to select for NOTCH2 and 3,
but not NOTCH1, interaction is unprecedented. The H268Q
missense mutation falls in the second EGF repeat, a region
involved in Notch receptor activation,37 close to a number
of patient-specific JAG1 mutations,1 and close to 3 inter-
acting amino acids in NOTCH1, in EGF9, and EGF10,7 2 of
which are conserved in NOTCH2 (L368 and P391);
whereas the Valine 392 in NOTCH1 is instead a Leucine in
NOTCH2. Whether this difference will explain the differ-
ential effect of the JAGGED1 H268Q mutation on NOTCH1
and 2 activation, however, remains to be tested. This dif-
ference cannot explain differences in binding to NOTCH3
because all 3 amino acids are conserved in NOTCH3
(Supplementary Materials).
The Recovery of Jag1Ndr/Ndr Mice Suggests
Endogenous Mechanisms can
Rescue Alagille Syndrome
Why certain patients with ALGS recover liver biliary func-
tion while others progress to liver transplantation is currently
unknown. Jag1Ndr/Ndr pups display a severe biliary phenotype
that is functionally rescued inadults. This is in contrast to Jag1þ/
dDSLmice, which display ALGS-like liver phenotypes in a C57bl6
background, but are not reported to improve with age.14
Sox9 is expressed not only in cholangiocytes, but also in
stem-like hepatocytes upon insult,9,38,39 which can trans-
differentiate into cholangiocytes. A similar rescue in adult
albumin-Cre Hnf6flox/flox Rbpjflox/flox mice40 suggests Notch-
independent mechanisms induce ductular reaction and
hepatocyte trans-differentiation. The recovery in Jag1Ndr/Ndr
mice may also be because of hepatocyte trans-
differentiation, which can be induced with Notch activa-
tion.28 Thus, although Notch is not required for rescue, it
may be sufficient. Transient activation of Notch may there-
fore – in principle – be feasible as therapy, though the role of
Notch signaling in cancer suggests this could be associatedwith significant risks.41,42 The loss of Igf1 also presents
an interesting therapeutic target because Igf1 stimulates
cholangiocyte proliferation.43
While Jag1Ndr/Ndr mice recovered biliary function they
did not recover hepatic artery numbers, suggesting that the
absence of proper portal triad vascular architecture does
not preclude recovery of a functional biliary tree. Thus,
cholangiocytes are not completely dependent on the
presence of a hepatic artery, which would otherwise be
suggested by the biliary breakdown induced by hepatic
artery ligation, and which would preclude cell replacement
therapy. Instead, our results suggest cell replacement ther-
apies to replace absent cholangiocytes may be feasible, even
in the absence of normal hepatic vasculature.
Our data, showing a selective loss of primarily Notch1-
mediated signaling, may be at apparent odds with the fact
that ALGS can be caused by NOTCH2 mutations,12 and that
compound heterozygous Jag1/Notch2 mice are also growth
delayed, display jaundice, and recapitulate hepatic, cardiac,
renal, and ocular defects.10 Moreover, Notch2 is required for
bile ductmorphogenesis anddifferentiation in vivo,44–46while
Notch1 is dispensable.44 However, themildly reduced Jag1Ndr-
Notch2 signaling described here may be sufficient to cause a
pathologic outcome in keeping with the dose-sensitive nature
of the Notch signaling pathway.
In sum, the Nodder mouse provides a clinically
relevant model for ALGS and allows for the first time a
Jag1 missense mutation to be linked both to phenotypic
traits typical for the disease and to dysregulated
Notch signaling, manifested by hypomorphic signaling
and receptor-selectivity.
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